Wedbush Securities Inc. lessened its stake in shares of Obseva SA (NASDAQ:OBSV) by 33.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,008 shares of the company’s stock after selling 12,782 shares during the period. Wedbush Securities Inc. owned about 0.06% of Obseva worth $294,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OBSV. Dimensional Fund Advisors LP raised its holdings in Obseva by 274.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock worth $893,000 after acquiring an additional 51,733 shares in the last quarter. Geode Capital Management LLC bought a new stake in Obseva during the fourth quarter worth about $159,000. Finally, Fosun International Ltd acquired a new position in Obseva during the first quarter worth approximately $2,494,000. Institutional investors and hedge funds own 63.55% of the company’s stock.
NASDAQ OBSV traded up $0.06 during trading on Friday, reaching $8.84. 28,000 shares of the company’s stock were exchanged, compared to its average volume of 60,445. The business has a 50 day moving average price of $9.95 and a 200-day moving average price of $11.95. The stock has a market capitalization of $399.29 million, a P/E ratio of -4.63 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.67 and a quick ratio of 3.67. Obseva SA has a fifty-two week low of $8.22 and a fifty-two week high of $19.40.
OBSV has been the topic of a number of recent analyst reports. HC Wainwright set a $44.00 price target on Obseva and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Royal Bank of Canada reissued a “buy” rating on shares of Obseva in a research report on Sunday, August 11th. Zacks Investment Research downgraded Obseva from a “hold” rating to a “sell” rating in a research report on Wednesday, July 31st. Credit Suisse Group lowered their price target on Obseva from $24.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, July 29th. Finally, ValuEngine raised Obseva from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.00.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: Buyback
Want to see what other hedge funds are holding OBSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Obseva SA (NASDAQ:OBSV).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.